阿克替苷对大鼠前列腺增生的组织形态及其对凋亡蛋白表达的影响

Effect of acteoside on rat prostatic hyperplasia tissue morphology and its influence on the expression of apoptosis protein and anti-apoptosis protein

目的研究阿克替苷对大鼠前列腺增生的组织形态及Bax和Bcl-2表达的影响。方法大鼠予以50 mg·kg^(-1)丙酸睾丸,隔日皮下注射,连续4周,构建前列腺增生模型。建模成功后,将其分为模型组、对照组和低、中、高3个剂量实验组,每组各10只。另取,10只正常大鼠作为空白组。空白组和模型组均予以等剂量0.9%Na Cl,灌胃;对照组予以0.8 mg·kg^(-1)非那雄胺,灌胃;低、中、高3个剂量实验组分别予以20,40,80 mg·kg^(-1)阿克替苷,灌胃。6组大鼠每天灌胃1次,连续6周。取各组大鼠前列腺组织并称重,计算前列腺指数。用组织切片观察各组大鼠前列腺组织的病理形态,用免疫印迹法检测各组大鼠前列腺Bax和Bcl-2蛋白的表达。结果空白组、模型组、对照组、低、中、高3个剂量实验组的前列腺湿重分别为(815.52±262.68),(1220.49±353.52),(1075.25±174.03),(1103.00±106.23),(816.12±132.87)和(815.37±106.81)mg,前列腺指数分别为(2.43±0.85)%,(3.74±0.78)%,(3.15±0.28)%,(3.10±0.22)%,(2.53±0.41)%和(2.48±0.37)%,Bax分别为(11.41±2.72)%,(8.49±2.01)%,(10.17±2.87)%,(9.09±1.98)%,(11.01±2.04)%和(11.10±1.91)%,Bcl-2分别为(7.79±1.74)%,(13.79±3.59)%,(10.23±2.74)%,(12.18±2.10)%,(8.53±2.62)%和(8.61±1.99)%,模型组、低剂量实验组的上述指标与中、高2个剂量实验组比较,差异均有统计学意义(均P<0.05)。结论阿克替苷能显著抑制前列腺增生,其机制可能是通过调节Bcl-2和Bax的表达,从而促进良性前列腺增生的细胞凋亡。

Objective To evaluate the effect of actinoside on the structure of hyperplasia of rats and the expression of Bax and Bcl - 2. Methods Rats received 50 mg · kg-1 testosterone propionate via subcu- taneous injection every other day nign prostatic hyperplasia model. , consecutive 4 weeks to construct be- After the model was established suc- eessfully, they were randomly divided into model group, control group, low dose group, middle dose group and high dose group with 10 rats per group. Another 10 normal rats were selected as blank group. Blank group and model group were given 0.9% NaC1, intragastric administration. Control group was given 0. 8 mg · kg-1finasteride, intragastric adminis- tration. Low dose test group, middle dose test group and high dose testgroup were given 20, 40 and 80 mg · kg-1 acteosidevia, intragastric administration, respectively. Six groups were trea- ted once a day for 6 weeks. The prostate index was calculated by taking the prostate tissue and weighing it. The histo- pathology of the prostate tissue of rats was examined by tissue biopsy, and the expressions of the prostate Bax and Bcl -2 proteins were measured by immunohistochemical method. Results The main indexes in blank, model, control, low dose, middle dose, high dose test groups were compared： the wet weight of prostate were （ 815.52 ± 262. 68 ）, （1220. 49 ±353.52）, （1075.25 ± 174. 03）, （ 1103.00 ± 106. 23）, （816. 12 ± 132. 87） and （815.37 ± 106. 81 ） mg, the prostate indexes were （2.43 ±0.85）%, （3.74 ±0.78）%, （3.15 ±0.28）%, （3.10 ±0.22）%, （2.53±0.41）% and （2.48 ±0.37）%, Bax were （11.41 ±2.72）%, （8.49 ±2.01）%, （10.17 ±2.87）%, （9. 09 ± 1.98）%, （11.01 ±2. 04）% and （11.10 ±1.91）%, Bcl-2 were （7.79 ± 1.74）%, （13.79 ±3.59）%, （10.23±2.74）%, （12. 18 ±2.10）%, （8.53 ±2.62）% and （8.61 ±1.99）%. Compared with model and low dose test groups, the differences were statistically significant with middle dose, high dose test groups （all P 〈 0. 05 ）. Conehmion Actinoside can significantly inhibit prostatic hyperplasia, and its mechanism may be by regulating the expression of Bcl -2 and Bax to promote the apoptosis of benign prostatic hyperplasia.